915411-54-0

Basic information

• Product Name: 3-Pyridinamine, N-[3-[(4-methoxyphenyl)methoxy]-5-[1-[tris(1-methylethyl)silyl]-1H-indol- 4-yl]phenyl]-6-(phenylmethoxy)-
• CAS NO: 915411-54-0
• Molecular Formula: C43H49N3O3Si
• Molecular Weight: 683.966
• Mol File: 915411-54-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 3-Pyridinamine, N-[3-[(4-methoxyphenyl)methoxy]-5-[1-[tris(1-methylethyl)silyl]-1H-indol- 4-yl]phenyl]-6-(phenylmethoxy)-(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Pyridinamine, N-[3-[(4-methoxyphenyl)methoxy]-5-[1-[tris(1-methylethyl)silyl]-1H-indol- 4-yl]phenyl]-6-(phenylmethoxy)-(915411-54-0)
• EPA Substance Registry System: 3-Pyridinamine, N-[3-[(4-methoxyphenyl)methoxy]-5-[1-[tris(1-methylethyl)silyl]-1H-indol- 4-yl]phenyl]-6-(phenylmethoxy)-(915411-54-0)

Safety Data

• Hazardous Substances Data: 915411-54-0(Hazardous Substances Data)

Upstream product

• 388116-27-6 indole-4-boronic acid pinacol ester 
• 20194-18-7 sodium phenyl-methanolate 
• 827-94-1 2,6-dibromo-4-nitroaniline 
• 6311-60-0 3,5-dibromonitrobenzene 
• 75926-65-7 3-amino-6-(benzyloxy)pyridine 
• 915410-93-4 1,3-dibromo-5-((4-methoxybenzyl)oxy)-benzene 
• 52488-36-5 4-bromo-1H-indole 
• 5350-93-6 6-Chloro-pyridin-3-ylamine 
• 690632-17-8 4-(4,4,5,5-tetramethyl-1,3,2-dioxoborolan-2-yl)-1-(triisopropylsilyl)-1H-indole 
• 915411-53-9 (6-benzyloxy-pyridin-3-yl)-[3-bromo-5-(4-methoxy-benzyloxy)-phenyl]-amine 

Relevant articles and documents

Anti-cancer agents and uses thereof

The present invention is in the area of novel compounds and salts thereof, their syntheses, and their use as anti-cancer agents. The compounds include compounds of Formula I: and solvates, hydrates and pharmaceutically-acceptable salts thereof, wherein A1 is N or CR1; A3 is N or CR3; A5 is N or CR5; R1, R3-R6 and L are defined in the specification; n is 0 or 1; and X is an optionally-substituted aryl group having 6-10 carbons in the ring portion, an optionally-substituted 6-membered heteroaryl group having 1-3 nitrogen atoms in the ring portion, an optionally-substituted 5-membered heteroaryl group having 0-4 nitrogen atoms in the ring portion and optionally having 1 sulfur atom or 1 oxygen atom in the ring portion, or an optionally-substituted heteroaryl group in which a 6-membered ring is fused either to a 5-membered ring or to a 6-membered ring, wherein in each case 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from nitrogen, oxygen and sulfur. They are effective against a broad range of cancers, especially leukemia, prostate, non-small cell lung and colon. They are additionally useful in the treatment of proliferative retinopathies such as diabetic neuropathy and macular degeneration.

Anti-cancer agents and uses thereof

The present invention is in the area of novel compounds and salts thereof, their syntheses, and their use as anti-cancer agents. The compounds include compounds of Formula I: and solvates, hydrates and pharmaceutically-acceptable salts thereof, wherein A1 is N or CR1; A3 is N or CR3; A5 is N or CR5; R1, R3—R6 and L are defined in the specification; n is 0 or 1; and X is an optionally-substituted aryl group having 6-10 carbons in the ring portion, an optionally-substituted 6-membered heteroaryl group having 1-3 nitrogen atoms in the ring portion, an optionally-substituted 5-membered heteroaryl group having 0-4 nitrogen atoms in the ring portion and optionally having 1 sulfur atom or 1 oxygen atom in the ring portion, or an optionally-substituted heteroaryl group in which a 6-membered ring is fused either to a 5-membered ring or to a 6-membered ring, wherein in each case 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from nitrogen, oxygen and sulfur. They are effective against a broad range of cancers, especially leukemia, non-small cell lung and colon.